HIV Infections Clinical Trial
Official title:
HIV Testing in the Emergency Department at Baystate Medical Center: A Pilot Program Version 1.5, May 2009
Background Recently, the CDC issued recommendations calling for HIV screening for patients
aged 13-64, when the individual accesses the health care system. For many patients, the
emergency department (ED) is the primary or only contact point for health care. The rapid
HIV test can be done as a point of care test in the ED.
Study Objectives
A. Primary:
1. To initiate HIV testing in the Baystate ED.
B. Secondary:
1. To estimate the resources involved in initiating a rapid HIV testing program in the ED.
2. To describe the process of initiating a rapid HIV testing program.
3. To compare the yield of testing for HIV in patients with known HIV risk factors
compared to those without known risk factors.
4. To describe the characteristics of the population tested for HIV in the ED.
5. To determine the number of patients who declined testing and the reasons for declining
testing.
6. To analyze ED staff attitudes re: HIV rapid testing in the ED.
Methods A trained HIV Educator/counselor will approach patients in the ED to offer free
rapid HIV testing, at a time they are not currently engaged with the health care provider.
Study informed consent and HIV consent will be obtained prior to testing. The HIV educator
will obtain demographic and clinical information on the enrolled subjects including prior
HIV testing and HIV risk factors. Patients testing negative will be counseled regarding HIV
risk reduction strategies. Patients with an initial positive rapid HIV test will have blood
drawn for confirmation (Western Blot) and will be referred to an HIV clinic for follow-up
and treatment. Additionally, to assess acceptability of rapid testing in the ED, a brief
anonymous electronic survey will be conducted of health care providers in the ED prior to
starting this pilot program and following the program.
Data Analysis The yield of testing will be calculated as will the seroprevalence of those
tested. Among patients who decline HIV testing but agree to study participation (sign
consent form), the number refusing testing will be recorded and reasons for refusing will be
analyzed. The yield of testing will be compared in patients with to those without known HIV
risk factors.
I. Background Recently, CDC issued recommendations calling for HIV screening for patients
aged 13-64, when the individual accesses the health care system 1. For many patients,
especially those without a primary care provider, the emergency department (ED) is the
primary or only contact point for the health care system. Testing individuals while they are
in the ED has the potential to identify persons who do not perceive themselves to be at risk
for HIV. Several academic EDs have begun to offer HIV testing 10, and have initially
indicated promising results.
II. Rationale for testing in ED Testing in the ED has several potential advantages. It leads
to shorter hospital stays, increases the number of newly diagnosed patients with HIV who are
discharged from the hospital aware of their HIV status, and improved entry into outpatient
care for patients admitted at the time of their initial HIV diagnosis. Another advantage of
HIV testing in the ED is the ability to link newly diagnosed patients to an HIV clinician.
The optimal approach to testing for HIV in the ED is not known. Testing without risk
assessment can identify persons with undiagnosed HIV infection and reduce reluctance
assessing risk behavior.
While widespread routine HIV screening (e.g. testing as many patients as possible presenting
to the ED) is likely to result in the highest number of positive tests, this strategy is
expensive, burdensome and will not be practical in a busy city ED. In the setting of limited
resources, a strategy of targeted testing (testing patients with established risk factors
for HIV) may be a more cost-effective strategy. It may also be more practical and may be
more acceptable to ED staff.
Another issue which needs further study is identifying the optimal personnel to conduct
rapid HIV testing in the ED. There are advantages and disadvantages to requiring ED staff to
counsel and consent patients for HIV testing. The ED staff may believe the testing is not in
their purview and may not believe they have time to devote to testing.
Another important issue is the feasibility of conducting rapid testing in the ED. How many
individuals can be tested in an eight hour day by one HIV educator? What are the barriers to
conducting rapid testing in the ED and what solutions can be implemented to overcome these
barriers? Finally, what are the attitudes of the ED staff regarding HIV testing in the ED?
By collecting data during the implementation of this pilot project we hope to optimize the
approach to HIV testing in the ED.
III. Hypothesis
Primary - Initiation of a rapid HIV testing program in the ED of a community teaching
hospital is feasible but will require substantial resources and cooperation between multiple
departments and stakeholders.
Secondary- Patients with known HIV risk factors will have a higher HIV seroprevalence
compared to patients without known risk factors.
IV. Study Objectives
A. Primary:
1. To initiate HIV testing in the Baystate ED in order to increase the number of new HIV
diagnoses and to link these patients to HIV care.
B. Secondary:
1. To estimate the resources involved in initiating a rapid HIV testing program in the ED
of a large community teaching hospital.
2. To describe the process of initiating a rapid HIV testing program and the barriers to
implementation.
3. To compare the yield of HIV testing in patients with known HIV risk factors compared to
those without known risk factors in patients presenting to the ED in order to estimate
the feasibility of a random screening strategy compared to a targeted screening
strategy.
4. To describe the characteristics of the population tested for HIV in the ED.
5. To determine the number of patients who decline testing and the reasons for declining
testing.
6. To determine the number of newly diagnosed individuals who were successfully linked to
an HIV provider and the number who received antiretroviral therapy within one year of
initial diagnosis.
7. To analyze ED staff attitudes re: HIV rapid testing in the ED
V. Methods:
Overview of Operations:
A trained HIV Health Educator will offer HIV counseling and testing to ED patients
interested in HIV testing. The number of patients studied will be determined by how many
patients can be approached by the HIV Health Educator.
Following initial counseling the HIV Health educator will obtain an Informed Consent for
study participation and HIV testing as well as HIPPA authorization from the study
participants. Patients who decline testing will be asked to consent to participate in the
study by signing a research consent form and will be asked the reason(s) they decline
testing. The reasons for declining testing will be recorded among those who agree to
participate.
ED patients may also be referred to the HIV Health Educator by the ED nurse or clinician
(physician or midlevel clinician) if the nurse or clinician believes HIV testing is
indicated based on potential risk factors for HIV or conditions possibly related to (as a
part of the patient's social and medical history). Finally, a patient who is an ED patient
(and has not otherwise been approached for testing) may also request to be tested for HIV
while in the ED.
After identification of potential patients according to one of the above methods, the health
educator will approach patients who are not otherwise engaged with an ED staff person and
prior to discharge from the ED. Patients will be approached in a fashion that does not
interfere with the normal flow of the ED visit. Patients too ill to approach (in the opinion
of the HIV health educator or ED staff) will be excluded, as will patients who have
previously tested positive for HIV. The HIV Health Educator will do an initial risk
assessment and brief pretest counseling prior to obtaining verbal and written consent for
HIV testing. Counseling and consent will be in Spanish for patients whose primary language
is Spanish. (A consent form will be translated into Spanish.) The Health Educator will then
obtain blood via finger stick from the patient. The test will be run (according to the
instructions in the package insert) by the Health Educator in a designated area of the ED.
Results will be read as reactive or non-reactive. In the event of a non-reactive test the
patient will be informed of the result. During the post-test counseling session patients
will be given risk reduction information and shown harm reduction skills and techniques and
counseled on appropriate behaviors to minimize risk of HIV acquisition. The patient will
also be offered an opportunity to be retested in the future and encouraged to visit an I-CTR
program for sexually transmitted disease and hepatitis testing and vaccinations as needed.
Testing will be entirely voluntary and will be confidential
In case of a reactive rapid test the client will be brought to the consultation room in the
ED to ensure privacy and will be informed that the result is a preliminary reactive result
for HIV and that a confirmatory test is required. In the case of a reactive test (initial
positive), a venous blood sample will be drawn by the HIV Health Educator for confirmation
via HIV Western blot. The HIV Health Educator is licensed to draw blood. A separate written
consent for HIV will be obtained prior to obtaining blood for the HIV Western blot. The
Western blot will be sent to the MA State laboratory with an expected result in < 5 business
days. The results of the initial test and the confirmatory test will not be entered into the
patient medical record. The state of Massachusetts Department of Health will not have the
names of patients tested. The only reporting to the state of positive HIV results will be
done when the patient accesses medical care as per state law e.g. the patient's health care
provider will report the results to the state. This reporting is not part of this study.
The HIV health educator has extensive experience in informing patients/clients of positive
HIV test results and has a plan in place to counsel such patients. The PI or his
representative will also be available to counsel patients with a positive HIV test result.
In the rare case of a catastrophic emotional reaction to a positive test result the HIV
health educator will involve the crisis team (Behavioral Health Network (BHN) Crisis
Services). The BHN crisis services team is stationed in the ED and has experience counseling
patients who are severely emotionally distraught. The BHN crisis team is aware of the HIV
rapid testing program and is willing to participate when needed. If the patient has problems
after he/she leaves the ED, he/she will be able to contact the HIV health educator who, in
conjunction with the PI, can then make a referral (if needed) for psychological/psychiatric
follow-up. Once the patient has followed up with a health care provider in the HIV/ID clinic
(generally within 5 days) (see below for details) if psychological issues arise that health
care provider will make an appropriate referral to a mental health provider.
In cases where the rapid HIV test is reactive, the HIV Health Educator will be responsible
for linking the patient to appropriate medical care. An appointment in the HIV/ID clinic
will be given to the patient prior to discharge from the ED.
The patient can be referred to any of the three Baystate Health Centers In the event where
the tested patient leaves the ED prior to receipt of test results the counselor will notify
the patient by phone or mail to schedule an appointment for receipt of results. A supportive
referral for mental health assessment and counseling will also be made, as needed (see
above).
Survey Prior to the start of rapid HIV testing in the ED, a brief electronic survey (using
Survey Monkey software) will be conducted. The survey will be sent via email to ED
physicians and midlevel providers. The survey instructions will explain that the survey is
voluntary and confidential and that participants will not be identified. The same survey
will be sent to the same individuals after the first six months of this pilot program to
assess any changes in attitudes.
VI. Data Management/Security
The HIV Health Educator will collect data for clinical and study purposes. Data will be
stored in paper records, not electronically. All patient information will be kept in
individual folders by barcode. A barcode is assigned to each patient and is used as a
specific identifier for each specimen tested. Once testing had been completed these folders
will be stored in a locked file in the office of the principal investigator. There is a
policy in place to maintain confidentiality and privacy throughout the entire testing
process: written consent, test performance, disclosure of test results, and storage of
records. We will not allow access to other researchers or answer any other questions without
IRB approval. All files will be kept for seven years.
VII. ANALYSIS PLAN
Demographic information obtained from the patient at the time of testing as part of the
pilot testing will be recorded on a data collection sheet. Data collected will include risk
factors for HIV, ethnicity, sex, age, payer status, zip code, homeless status, prior testing
status (and dates of prior testing), co-morbid medical conditions possibly related to HIV
diagnosis and chief complaint on presentation to ED. In addition, general demographic
information about patients admitted to the ED during the study period will be requested and
de-identified and, if appropriate, will be extrapolated for calculation of seroprevalence
e.g. the characteristics of the patients tested for HIV will be compared to the overall ED
population in order to ascertain whether the tested sample is representative of the ED
population.
The number of patients approached for testing will be recorded as will the total number of
patients registered in the ED during the period of testing (eight hours per day, five days
per week). The number of reactive tests as well as the number of positive confirmatory tests
will be determined. In order to determine the yield of testing and to estimate
seroprevalence in the ED, the number of patients testing positive (confirmed by Western
blot) will be divided by the total number tested. Further calculations will incorporate the
yield of testing in those with risk factors and compare to those with no reported risk
factors. In addition, the number of patients with reactive tests attending an initial and
subsequent HIV clinic visit as well as the number presenting with an AIDS diagnosis and the
number commencing antiretroviral therapy within one year after testing will be recorded.
The HIV health educator will observe and record barriers to testing in the ED staff..
Modifications in the testing policy will be implemented based on the assessment of the HIV
health educator in order to maximize the number of patients tested. No identifying
information concerning ED staff members will be recorded. Modifications in the testing
policy will be implemented based on this assessment in order to maximize the number of
patients tested.
In order to ascertain the sustainability of the program, following the initial pilot
program, the cost of HIV testing will be estimated by including the following costs: health
educator salary plus benefits, program administration, materials, test kits, postage and
confirmatory testing. The cost per test, cost per approached patient, cost per enrolled
patient, and cost per confirmed infection detected will be calculated, as will the
annualized direct cost.
Results of the survey will be tallied. Pre and post surveys will be compared using Chi
square for categorical data (e.g. for yes, no questions) and Student's T test for continuous
data.
Data from the main study will be entered into Microsoft Excel. StatView statistical software
will be used to analyze data. Categorical data will be analyzed by the appropriate test e.g.
Chi Square or Fisher's exact test. Continuous data will be analyzed using the Student's
T-test.
;
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |